Hyderabad: Indian pharmaceutical company Hetero on 29th July announced the launch of generic Favipiravir in India market under the brand name 'Favivir.' Hetero has been granted the manufacturing and marketing approval for Favipiravir from the Drug Controller General of India (DCGI).
According to the manufacturers, Favivir is the second drug developed by Hetero after Covifor (Remdesivir) used in the treatment of Covid-19. 'It is an oral antiviral medication that has demonstrated positive clinical outcomes. Favivir improves treatment accessibility to a significant amount of Covid 19 patient population, which usually sustains mild to moderate symptoms" Hetero said in a statement.
Hetero's Favivir is priced at Rs. 59 per tablet and is marketed and distributed by Hetero Healthcare Limited. The product is available from 29th July onwards at all retail medical outlets and hospital pharmacies across the country and will be sold only on prescription.